Irvine, CA (PRWEB) April 30, 2013
EP Global Communications, Inc. (the Company), (Stock Ticker: EPGL) announces that it will host a conference call tonight, Tuesday April 30, 2013 at 6:00PM Eastern Time. The call will include the full team of doctors involved with EPGL's new "Topspin" advanced MEMS technology platform for medical device development. This will include one of the world's top BioMEMS engineers; David T. Markus Ph.D. The first 100 interested persons can attend tonight's call by dialing in at 604-475-4000 and entering Code 475116#.
EPGL is the only medical device company to possess the advanced "TopSpin" MEMS technology platform which was developed by top BioMEMS engineer David T. Markus, Ph.D. "EPGL possesses advanced medical device technology that will bring in the smartest and most innovative new medical devices to market. We are years ahead of our competition in know-how and our TopSpin platform can be the catalyst for literally hundreds of new devices to benefit medicine. The prototypes we have under development represent a paradigm shift in technology for medical devices."
About David T. Markus, Ph.D. Vice President - BioMems Development:
David T. Markus holds a Ph.D. in Biomedical Engineering and a MS in Electrical Engineering with an emphasis in MEMS Microelectronics and Biomedical. Dr. Markus spent 11 years with Raytheon and holds 8 US patents and has 9 other US Patents Pending. He has been involved in research for several of the world's leading technological institutions, including the Office of Naval Research in Arlington, Virginia, NASA Jet Propulsion Laboratory in Pasadena, CA and he has been published 15 times for various technical conferences. He was a principal investigator on SBIR DARPA Phase I and Phase II, and "Ultraflexible Substrate" for Macroelectronics Program by Dr. Robert Reuss at DARPA. He has been involved in the engineering and the development on seven surgical devices, including devices for Cataract surgery, Intra-Ocular Lens Delivery, Arthroscopy, Endodontic Endoscope, Micro Endoscope and Neural Electrodes. Additionally he was instrumental on developing three medical laboratory devices, including for In-Vitro Fertilization, PCR instrumentation and drug discovery. Finally, Dr. Markus is fluent in English, Chinese-Madarin, Taiwanese-FuJian and Indonesian languages.
About EP Global Communications, Inc. / EPGL Medical
EP Global Communications, Inc. is a medical device manufacturer and marketing company with exclusive rights to a new FDA 510k cleared medical device called the Muscle Pain Detection Device. The MPDD is a revolutionary new diagnostic tool for the detection of muscular originated pain in the human body.
Safe Harbor Statement
Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the timing of projects due to the variability in size, scope and duration of projects, estimates made by management with respect to the Company's critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Read the full story at http://www.prweb.com/releases/2013/4/prweb10684273.htm.
Copyright©2012 Vocus, Inc.
All rights reserved